GeneDx Faces Securities Class Action After 49% Stock Plunge
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 05 2026
0mins
Source: PRnewswire
- Stock Plunge: GeneDx's stock price plummeted by $33.42 (-49%) on May 5, 2026, following a disastrous Q1 2026 earnings report, severely undermining investor confidence and potentially triggering widespread sell-offs.
- Lawsuit Background: Hagens Berman is investigating whether GeneDx violated federal securities laws, with the lawsuit aiming to represent investors who purchased shares between April 16, 2025, and May 4, 2026, seeking compensation for their losses.
- Deteriorating Financial Performance: GeneDx reported a tenfold increase in net loss for Q1 2026 compared to the previous year, with the Fabric Genomics business missing revenue targets and leading to a $31.2 million impairment charge, significantly impacting the company's financial health.
- Revenue Guidance Cut: The company slashed its 2026 revenue guidance by 12%, stating that genome and exome revenue growth would be at least 20%, a stark decline from previous expectations, reflecting significant changes in product mix and negative implications for future growth.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy WGS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on WGS
Wall Street analysts forecast WGS stock price to rise
8 Analyst Rating
7 Buy
1 Hold
0 Sell
Strong Buy
Current: 60.990
Low
155.00
Averages
171.43
High
200.00
Current: 60.990
Low
155.00
Averages
171.43
High
200.00
About WGS
GeneDx Holdings Corp. is a genomics company. The Company operates, through its subsidiary, GeneDx, LLC, which is focused on exome and genome tests that translate complex genomic data into clinical answers that unlock personalized health plans, accelerate drug discovery, and improve health system efficiencies. It operates through GeneDx segment, which primarily provides pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing and, to a lesser extent, data and information services. Exome sequencing test options include XomeDx, XomeDx Plus, and XomeDxXpress. GeneDx genome sequencing evaluates the protein-coding and non-coding regions of an individual’s nuclear genome. GeneDx genome sequencing test options include GenomeSeqDx and GenomeXpress. It offers a menu of targeted variant testing options to meet the needs of families and healthcare providers. Its subsidiary, Fabric Genomics, Inc., specializes in artificial intelligence-powered genomic interpretation.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
GeneDx Faces Securities Class Action After 49% Stock Plunge
- Stock Plunge: GeneDx's stock plummeted by $33.42 (-49%) on May 5, 2026, following a disastrous Q1 2026 earnings report, indicating a severe loss of investor confidence and a dramatic deterioration in the company's financial health.
- Class Action Initiated: Hagens Berman is investigating whether GeneDx violated federal securities laws, seeking to represent investors who purchased shares between April 16, 2025, and May 4, 2026, highlighting a crisis of trust in the company's disclosures.
- Deteriorating Financial Performance: The company reported a tenfold increase in net loss for Q1 2026 compared to the previous year, with Fabric Genomics contributing to a $31.2 million impairment charge, showcasing the failure of the acquisition and a decline in profitability.
- Revenue Guidance Cut: GeneDx slashed its 2026 revenue guidance by 12%, stating that revenue growth for genome and exome would be at least 20%, significantly lower than previous expectations, underscoring management's pessimistic outlook on future growth.
See More
Faruqi & Faruqi Investigates GeneDx Securities Fraud Claims
- Legal Investigation Launched: Faruqi & Faruqi LLP is investigating potential securities fraud claims against GeneDx Holdings Corp., specifically targeting investors who purchased shares between April 16, 2025, and May 4, 2026, and reminding them to apply for lead plaintiff status by August 3, 2026, to represent other investors in the federal securities class action.
- Financial Miss Disclosure: On May 4, 2026, GeneDx disclosed that its Q1 financial results missed expectations, leading to a downward revision of its 2026 revenue guidance from $540-555 million to $475-490 million, indicating vulnerabilities in the company's market position that could undermine investor confidence.
- Stock Price Plunge Impact: Following the financial miss announcement, GeneDx's stock price plummeted over 49%, or $33.42 per share, in a single day, reflecting severe market concerns regarding the company's future profitability and potentially resulting in significant losses for investors.
- Investor Rights Protection: Faruqi & Faruqi LLP encourages all investors who purchased GeneDx stock during the class period and suffered losses to contact them to discuss their legal rights, ensuring that investors can secure their rightful claims in any potential recovery.
See More
Biotech Companies See Significant Stock Gains
- Gelteq Stock Surge: Australia-based Gelteq's shares soared over 197% without specific news, as the company commenced its first clinical trial for an antiparasitic drug candidate, which is expected to drive an FDA submission and enhance market competitiveness.
- Adial Acquires Azora: Adial Pharmaceuticals announced the acquisition of Azora Therapeutics with up to $64 million in financing, which will strengthen its pipeline for treating serious inflammatory diseases, with a Phase I clinical trial planned for 2027 expected to create new growth opportunities.
- Precigen Commercial Momentum: Precigen's PAPZIMEOS sales reached $21.6 million in Q1 2026, a significant increase from $3.4 million in Q4 2025, indicating strong commercialization momentum in the U.S. market, with expectations for further market share expansion.
- Eloxx Nasdaq Uplisting: Eloxx Pharmaceuticals' stock rose over 14% following its uplisting to Nasdaq, with plans to initiate a Phase 2b clinical trial for its lead drug Exaluren targeting Alport syndrome in Q3 2026, which is expected to provide new growth opportunities for the company.
See More
GeneDx Faces Class Action Lawsuit Amid Significant Stock Drop
- Class Action Filed: Pomerantz LLP has initiated a class action lawsuit against GeneDx Holdings Corp., alleging securities fraud and other unlawful business practices, with investors needing to apply as Lead Plaintiff by August 3, 2026.
- Deteriorating Financials: GeneDx's Q1 2026 results revealed a drop in adjusted gross margin from 74% to 69%, with projected earnings revised down from $540-$555 million to $475-$490 million, alongside a $31.3 million impairment loss linked to the acquisition of Fabric Genomics.
- Stock Price Plummet: Following the disappointing financial report, GeneDx's stock price fell by $33.42, or 49.20%, closing at $34.51 on May 5, 2026, indicating significant market concerns regarding the company's future outlook.
- Potential Legal Consequences: The class action lawsuit could expose GeneDx to substantial damages, exacerbating investor skepticism about the company's governance and financial transparency, which may adversely affect its market credibility and shareholder value.
See More
GeneDx Holdings Faces Class Action Lawsuit Over Misleading Statements
- Acquisition Impact Investigation: Robbins LLP is investigating whether GeneDx Holdings Corp. (WGS) misled investors regarding the positive financial impact of its $51 million acquisition of Fabric Genomics announced in April 2025, which was intended to expand market reach and revenue streams.
- Declining Financial Performance: On May 4, 2026, GeneDx reported first-quarter results that missed revenue estimates, lowering its full-year guidance from $540 million to a range of $475 million to $490 million, indicating adverse effects from the Fabric acquisition that undermined investor confidence.
- Stock Price Plummet: Following the disappointing financial results, GeneDx's stock price fell by $33.42, or 49.2%, reflecting severe market concerns about the company's future profitability and potentially prompting more investors to seek legal recourse.
- Legal Action Opportunity: Affected shareholders may participate in the class action lawsuit, with Robbins LLP offering contingency-based legal services aimed at helping shareholders recover losses and improve corporate governance, demonstrating a commitment to shareholder rights.
See More
Eli Casdin Increases Stake in GeneDx Holdings
- Stake Acquisition Overview: Eli Casdin, through his hedge fund Casdin Capital, purchased 200,000 shares of GeneDx in early June for approximately $11.1 million, following a prior acquisition of 500,000 shares in May, indicating strong confidence in the company's future prospects.
- Transaction Scale Analysis: The recent purchase of 690,000 shares totaled $32.57 million, significantly increasing Casdin Capital's stake in GeneDx, with May's acquisition representing nearly 17% of total holdings and June's purchase accounting for about 6%.
- Ownership Structure Changes: Post-transaction, Eli Casdin directly holds 20,517 shares and indirectly holds 3,859,555 shares, demonstrating his sustained investment through entities like Casdin Partners Master Fund, L.P., thereby enhancing his influence within the company.
- Market Outlook: Casdin's accumulation of shares is viewed as a bullish signal for GeneDx, especially as the company's stock price has fallen 67% from its five-year peak, suggesting he sees the current price as an attractive entry point that may draw further investor interest.
See More
GeneDx Faces Securities Class Action After 49% Stock Plunge
- Stock Plunge: GeneDx's stock plummeted by $33.42 (-49%) on May 5, 2026, following a disastrous Q1 2026 earnings report, indicating a severe loss of investor confidence and a dramatic deterioration in the company's financial health.
- Class Action Initiated: Hagens Berman is investigating whether GeneDx violated federal securities laws, seeking to represent investors who purchased shares between April 16, 2025, and May 4, 2026, highlighting a crisis of trust in the company's disclosures.
- Deteriorating Financial Performance: The company reported a tenfold increase in net loss for Q1 2026 compared to the previous year, with Fabric Genomics contributing to a $31.2 million impairment charge, showcasing the failure of the acquisition and a decline in profitability.
- Revenue Guidance Cut: GeneDx slashed its 2026 revenue guidance by 12%, stating that revenue growth for genome and exome would be at least 20%, significantly lower than previous expectations, underscoring management's pessimistic outlook on future growth.
See More
Faruqi & Faruqi Investigates GeneDx Securities Fraud Claims
- Legal Investigation Launched: Faruqi & Faruqi LLP is investigating potential securities fraud claims against GeneDx Holdings Corp., specifically targeting investors who purchased shares between April 16, 2025, and May 4, 2026, and reminding them to apply for lead plaintiff status by August 3, 2026, to represent other investors in the federal securities class action.
- Financial Miss Disclosure: On May 4, 2026, GeneDx disclosed that its Q1 financial results missed expectations, leading to a downward revision of its 2026 revenue guidance from $540-555 million to $475-490 million, indicating vulnerabilities in the company's market position that could undermine investor confidence.
- Stock Price Plunge Impact: Following the financial miss announcement, GeneDx's stock price plummeted over 49%, or $33.42 per share, in a single day, reflecting severe market concerns regarding the company's future profitability and potentially resulting in significant losses for investors.
- Investor Rights Protection: Faruqi & Faruqi LLP encourages all investors who purchased GeneDx stock during the class period and suffered losses to contact them to discuss their legal rights, ensuring that investors can secure their rightful claims in any potential recovery.
See More
Biotech Companies See Significant Stock Gains
- Gelteq Stock Surge: Australia-based Gelteq's shares soared over 197% without specific news, as the company commenced its first clinical trial for an antiparasitic drug candidate, which is expected to drive an FDA submission and enhance market competitiveness.
- Adial Acquires Azora: Adial Pharmaceuticals announced the acquisition of Azora Therapeutics with up to $64 million in financing, which will strengthen its pipeline for treating serious inflammatory diseases, with a Phase I clinical trial planned for 2027 expected to create new growth opportunities.
- Precigen Commercial Momentum: Precigen's PAPZIMEOS sales reached $21.6 million in Q1 2026, a significant increase from $3.4 million in Q4 2025, indicating strong commercialization momentum in the U.S. market, with expectations for further market share expansion.
- Eloxx Nasdaq Uplisting: Eloxx Pharmaceuticals' stock rose over 14% following its uplisting to Nasdaq, with plans to initiate a Phase 2b clinical trial for its lead drug Exaluren targeting Alport syndrome in Q3 2026, which is expected to provide new growth opportunities for the company.
See More
GeneDx Faces Class Action Lawsuit Amid Significant Stock Drop
- Class Action Filed: Pomerantz LLP has initiated a class action lawsuit against GeneDx Holdings Corp., alleging securities fraud and other unlawful business practices, with investors needing to apply as Lead Plaintiff by August 3, 2026.
- Deteriorating Financials: GeneDx's Q1 2026 results revealed a drop in adjusted gross margin from 74% to 69%, with projected earnings revised down from $540-$555 million to $475-$490 million, alongside a $31.3 million impairment loss linked to the acquisition of Fabric Genomics.
- Stock Price Plummet: Following the disappointing financial report, GeneDx's stock price fell by $33.42, or 49.20%, closing at $34.51 on May 5, 2026, indicating significant market concerns regarding the company's future outlook.
- Potential Legal Consequences: The class action lawsuit could expose GeneDx to substantial damages, exacerbating investor skepticism about the company's governance and financial transparency, which may adversely affect its market credibility and shareholder value.
See More
GeneDx Holdings Faces Class Action Lawsuit Over Misleading Statements
- Acquisition Impact Investigation: Robbins LLP is investigating whether GeneDx Holdings Corp. (WGS) misled investors regarding the positive financial impact of its $51 million acquisition of Fabric Genomics announced in April 2025, which was intended to expand market reach and revenue streams.
- Declining Financial Performance: On May 4, 2026, GeneDx reported first-quarter results that missed revenue estimates, lowering its full-year guidance from $540 million to a range of $475 million to $490 million, indicating adverse effects from the Fabric acquisition that undermined investor confidence.
- Stock Price Plummet: Following the disappointing financial results, GeneDx's stock price fell by $33.42, or 49.2%, reflecting severe market concerns about the company's future profitability and potentially prompting more investors to seek legal recourse.
- Legal Action Opportunity: Affected shareholders may participate in the class action lawsuit, with Robbins LLP offering contingency-based legal services aimed at helping shareholders recover losses and improve corporate governance, demonstrating a commitment to shareholder rights.
See More
Eli Casdin Increases Stake in GeneDx Holdings
- Stake Acquisition Overview: Eli Casdin, through his hedge fund Casdin Capital, purchased 200,000 shares of GeneDx in early June for approximately $11.1 million, following a prior acquisition of 500,000 shares in May, indicating strong confidence in the company's future prospects.
- Transaction Scale Analysis: The recent purchase of 690,000 shares totaled $32.57 million, significantly increasing Casdin Capital's stake in GeneDx, with May's acquisition representing nearly 17% of total holdings and June's purchase accounting for about 6%.
- Ownership Structure Changes: Post-transaction, Eli Casdin directly holds 20,517 shares and indirectly holds 3,859,555 shares, demonstrating his sustained investment through entities like Casdin Partners Master Fund, L.P., thereby enhancing his influence within the company.
- Market Outlook: Casdin's accumulation of shares is viewed as a bullish signal for GeneDx, especially as the company's stock price has fallen 67% from its five-year peak, suggesting he sees the current price as an attractive entry point that may draw further investor interest.
See More
